Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

This study has been terminated.
(Study terminated due to low accrual.)
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT01015300
First received: November 16, 2009
Last updated: May 9, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2012
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)